Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington's disease Ruchika Sharma3 Dec 2024 1:30 PM ISTBasel: Novartis has announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for PTC518.PTC518 is an...
Novartis Kisqali gets European Commission nod in patients with HR+/HER2-early breast cancer at high risk of recurrence Ruchika Sharma28 Nov 2024 12:59 PM ISTBasel: Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI)...
Novartis Healthcare gets CDSCO Panel nod to study Iptacopan Dr. Divya Colin24 Nov 2024 5:45 PM ISTNew Delhi: The drug major Novartis Healthcare has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Despite Pluvicto, MorphoSys Setbacks, Novartis Raises 2028 Sales Growth Outlook to 6% Farhat Nasim24 Nov 2024 10:30 AM ISTFrankfrut: Novartis raised its medium-term sales guidance on Thursday to 6 percent annual growth through 2028, driven by momentum of launched...
Eli Lilly's Experimental Drug Muvalaplin Lowers Inherited Cholesterol by Up to 86 percent Farhat Nasim20 Nov 2024 1:05 PM ISTRuth Gimeno, Lilly's group vice president for diabetes and metabolic research, said Eli Lilly is weighing next steps for advancing to late stage...
Ratio enters license, collaboration agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate Ruchika Sharma19 Nov 2024 1:30 PM ISTBoston: Ratio Therapeutics Inc, has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary...
CDSCO Panel Approves Novartis's Protocol Amendment Proposal to Study Ianalumab Dr. Divya Colin1 Nov 2024 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO Panel Approves Novartis Protocol Amendment Proposal to study Ribociclib Dr. Divya Colin28 Oct 2024 5:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis' Ribociclib named as Category 1 Preferred Adjuvant Treatment for Breast Cancer in NCCN Guidelines Farhat Nasim27 Oct 2024 10:15 AM ISTBasel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib...
Abbott's review plea challenging NPPA ceiling price fixation of 18 formulations rejected by DoP Farhat Nasim16 Oct 2024 4:59 PM ISTNew Delhi: The Department of Pharmaceuticals (DoP) has dismissed two review applications filed by Abbott Healthcare Private Limited (AHPL) challenging...
Switzerland COMCO competition commission terminates Novartis probe without consequences Ruchika Sharma11 Oct 2024 12:30 PM ISTBerlin: Switzerland's COMCO competition commission said on Thursday that it has terminated a probe against Novartis into possibly using blocking...
USFDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer Ruchika Sharma18 Sept 2024 3:04 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase...
